NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

Trial Profile

NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Sorafenib (Primary) ; Cyclophosphamide; Topotecan
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Acronyms N2013-02
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
    • 11 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
    • 21 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top